NASDAQ: RENB - Renovaro Biosciences Inc.

छह महीने के लिए लाभप्रदता: +19.76%
भाग प्रतिफल: 0.00%
सेक्टर: Healthcare

पदोन्नति कार्यक्रम Renovaro Biosciences Inc.


कंपनी के बारे में Renovaro Biosciences Inc.

Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV.

अधिक जानकारी
It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

IPO date 2015-02-02
ISIN US29350E1047
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.renovarobio.com
Цена ао 0.674
प्रति दिन मूल्य परिवर्तन: -10.95% (0.65)
प्रति सप्ताह मूल्य परिवर्तन: -17.43% (0.701)
प्रति माह मूल्य परिवर्तन: -51.36% (1.19)
3 महीने में कीमत में बदलाव: -36.89% (0.9171)
छह महीने में कीमत में बदलाव: +19.76% (0.4833)
प्रति वर्ष मूल्य परिवर्तन: -78.16% (2.65)
3 वर्षों में मूल्य परिवर्तन: -90.77% (6.27)
5 वर्षों में मूल्य परिवर्तन: -84.27% (3.68)
वर्ष की शुरुआत से मूल्य परिवर्तन: -65.13% (1.66)

बहुत मूल्यवान समझना

नाम अर्थ श्रेणी
P/S 0 0
P/BV 1.16 9
P/E 0 0
EV/EBITDA -1.97 0
कुल: 3.13

क्षमता

नाम अर्थ श्रेणी
ROA, % -72.84 0
ROE, % -90.37 0
कुल: 0

लाभांश

नाम अर्थ श्रेणी
Div yield, % 0 0
DSI 0 0
कुल: 0

कर्तव्य

नाम अर्थ श्रेणी
Debt/EBITDA -0.0476 10
कुल: 10

विकास का आवेग

नाम अर्थ श्रेणी
लाभप्रदता Revenue, % 42.56 6
लाभप्रदता Ebitda, % 609.97 10
लाभप्रदता EPS, % 241.32 10
कुल: 7.4

संस्थानों आयतन शेयर करना, %
Vanguard Group Inc 390107 1.01
Morgan Stanley 362978 0.94
Geode Capital Management, LLC 362409 0.93
Blackrock Inc. 304656 0.79
Millennium Management LLC 126314 0.33
Susquehanna International Group, LLP 119459 0.31
State Street Corporation 97687 0.25
Northern Trust Corporation 88101 0.23
683 Capital Management LLC 73706 0.19
Qube Research & Technologies Ltd 67978 0.18



पर्यवेक्षक नौकरी का शीर्षक भुगतान जन्म का साल
Dr. Francois Binette M.Sc., Ph.D. COO and Executive VP for Research & Development 504.38k 1964 (61 वर्ष)
Dr. Serhat Gümrükcü Co-Founder & Inventor N/A
Mr. Greg Duczynski Ph.D. Senior Vice President for Clinical Operations N/A
Hon. Mark R. Dybul M.D. CEO, Director & Member of HBV Scientific Advisory Board 764.58k 1963 (62 वर्ष)
Mr. Simon Tarsh Interim Chief Financial Officer N/A 1961 (64 वर्ष)

पता: United States, Los Angeles. CA, 2080 Century Park East - Google मानचित्र में खोलें, यांडेक्स मानचित्र खोलें
वेबसाइट: https://www.renovarobio.com